Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has released its Quality, Innovation, and Corporate Responsibility Report. The report covers the period from January 1, 2023, to September 30, 2024, and highlights the company's commitment to responsible operations in the healthcare industry.
Key achievements include:
- Operational Excellence: 88% of genetic testing samples were processed within industry-leading turnaround times, and the company achieved a net promoter score of 72 among providers as of July 2024.
- Innovation: Continued development of new technologies like the molecular residual disease (MRD) assay and modernization of facilities under the Labs of the Future initiative, aimed at improving workflows, reducing turnaround times, and cutting operating costs.
- Corporate Responsibility: In 2024, 84% of employees rated Myriad as a great place to work, 27 percentage points higher than the typical U.S. company. The company also recycled 46.9 tons of plastic from its Salt Lake City laboratories during the reporting period.
These efforts reflect Myriad's mission to make genetic testing more accessible, help patients manage their health, and support healthcare providers in preventing and treating disease.
Myriad Genetics (NASDAQ: MYGN), un leader nel settore dei test genetici e della medicina di precisione, ha pubblicato il suo Rapporto sulla Qualità, Innovazione e Responsabilità Aziendale. Il rapporto copre il periodo dal 1 gennaio 2023 al 30 settembre 2024 e mette in evidenza l'impegno dell'azienda per operazioni responsabili nel settore sanitario.
I principali risultati includono:
- Eccellenza Operativa: L'88% dei campioni di test genetici è stato elaborato entro tempi di risposta leader del settore, e l'azienda ha ottenuto un punteggio netto di promoter di 72 tra i fornitori a luglio 2024.
- Innovazione: Sviluppo continuo di nuove tecnologie come l'assay della malattia residua molecolare (MRD) e modernizzazione delle strutture nell'ambito dell'iniziativa Labs of the Future, volta a migliorare i flussi di lavoro, ridurre i tempi di risposta e abbattere i costi operativi.
- Responsabilità Aziendale: Nel 2024, l'84% dei dipendenti ha valutato Myriad come un ottimo posto di lavoro, 27 punti percentuali in più rispetto alla tipica azienda statunitense. L'azienda ha anche riciclato 46,9 tonnellate di plastica dai suoi laboratori di Salt Lake City durante il periodo di reporting.
Questi sforzi riflettono la missione di Myriad di rendere i test genetici più accessibili, aiutare i pazienti a gestire la propria salute e supportare i fornitori di servizi sanitari nella prevenzione e nel trattamento delle malattie.
Myriad Genetics (NASDAQ: MYGN), un líder en pruebas genéticas y medicina de precisión, ha publicado su Informe sobre Calidad, Innovación y Responsabilidad Corporativa. El informe abarca el período del 1 de enero de 2023 al 30 de septiembre de 2024 y destaca el compromiso de la empresa con operaciones responsables en la industria de la salud.
Los logros clave incluyen:
- Excelencia Operativa: El 88% de las muestras de pruebas genéticas se procesaron dentro de tiempos de respuesta líderes en la industria, y la empresa logró un puntaje neto de promotor de 72 entre los proveedores en julio de 2024.
- Innovación: Desarrollo continuo de nuevas tecnologías como el ensayo de enfermedad residual molecular (MRD) y modernización de instalaciones bajo la iniciativa Labs of the Future, destinada a mejorar flujos de trabajo, reducir tiempos de respuesta y disminuir costos operativos.
- Responsabilidad Corporativa: En 2024, el 84% de los empleados calificó a Myriad como un gran lugar para trabajar, 27 puntos porcentuales más alto que la típica empresa estadounidense. La empresa también recicló 46,9 toneladas de plástico de sus laboratorios en Salt Lake City durante el período del informe.
Estos esfuerzos reflejan la misión de Myriad de hacer que las pruebas genéticas sean más accesibles, ayudar a los pacientes a gestionar su salud y apoyar a los proveedores de atención médica en la prevención y el tratamiento de enfermedades.
Myriad Genetics (NASDAQ: MYGN), 유전자 검사 및 정밀 의학 분야의 선두주자로, 품질, 혁신 및 기업 책임 보고서를 발표했습니다. 이 보고서는 2023년 1월 1일부터 2024년 9월 30일까지의 기간을 다루며, 의료 산업에서 책임 있는 운영에 대한 회사의 의지를 강조합니다.
주요 성과는 다음과 같습니다:
- 운영 우수성: 유전자 검사 샘플의 88%가 업계 최고의 처리 시간 내에 처리되었으며, 2024년 7월 기준으로 제공자들 사이에서 72의 순추천자 점수를 달성했습니다.
- 혁신: 분자 잔여 질병(MRD) 검사와 같은 새로운 기술의 지속적인 개발과 미래의 실험실(Labs of the Future) 이니셔티브의 일환으로 시설 현대화를 통해 작업 흐름 개선, 처리 시간 단축 및 운영 비용 절감을 목표로 하고 있습니다.
- 기업 책임: 2024년 84%의 직원이 Myriad를 훌륭한 직장으로 평가했으며, 이는 미국의 일반 기업보다 27% 포인트 높은 수치입니다. 또한, 보고 기간 동안 Salt Lake City의 실험실에서 46.9톤의 플라스틱을 재활용했습니다.
이러한 노력은 유전자 검사를 보다 접근 가능하게 하고, 환자가 건강을 관리하도록 돕고, 의료 제공자가 질병을 예방하고 치료하는 데 지원하는 Myriad의 사명을 반영합니다.
Myriad Genetics (NASDAQ: MYGN), un leader dans les tests génétiques et la médecine de précision, a publié son Rapport sur la Qualité, l'Innovation et la Responsabilité Sociétale. Le rapport couvre la période du 1er janvier 2023 au 30 septembre 2024 et met en évidence l'engagement de l'entreprise envers des opérations responsables dans le secteur de la santé.
Les principales réalisations comprennent :
- Excellence Opérationnelle : 88 % des échantillons de tests génétiques ont été traités dans des délais de réponse leaders dans l'industrie, et l'entreprise a obtenu un score net de promoteur de 72 parmi les fournisseurs en juillet 2024.
- Innovation : Développement continu de nouvelles technologies comme l'essai de maladie résiduelle moléculaire (MRD) et modernisation des installations dans le cadre de l'initiative Labs of the Future, visant à améliorer les flux de travail, réduire les délais de traitement et diminuer les coûts d'exploitation.
- Responsabilité Sociétale : En 2024, 84 % des employés ont évalué Myriad comme un excellent lieu de travail, soit 27 points de pourcentage de plus que l'entreprise américaine typique. L'entreprise a également recyclé 46,9 tonnes de plastique provenant de ses laboratoires de Salt Lake City pendant la période de reporting.
Ces efforts reflètent la mission de Myriad de rendre les tests génétiques plus accessibles, d'aider les patients à gérer leur santé et de soutenir les prestataires de soins de santé dans la prévention et le traitement des maladies.
Myriad Genetics (NASDAQ: MYGN), ein führendes Unternehmen im Bereich genetischer Tests und Präzisionsmedizin, hat seinen Bericht über Qualität, Innovation und Unternehmensverantwortung veröffentlicht. Der Bericht umfasst den Zeitraum vom 1. Januar 2023 bis zum 30. September 2024 und hebt das Engagement des Unternehmens für verantwortungsbewusste Abläufe in der Gesundheitsbranche hervor.
Wichtige Erfolge sind:
- Betriebliche Exzellenz: 88% der genetischen Testproben wurden innerhalb branchenführender Bearbeitungszeiten verarbeitet, und das Unternehmen erzielte im Juli 2024 einen Net Promoter Score von 72 unter den Anbietern.
- Innovation: Fortlaufende Entwicklung neuer Technologien wie dem molekularen Residualkrankheit (MRD) Assay und die Modernisierung von Einrichtungen im Rahmen der Initiative Labs of the Future, die darauf abzielt, Arbeitsabläufe zu verbessern, Bearbeitungszeiten zu verkürzen und Betriebskosten zu senken.
- Unternehmensverantwortung: Im Jahr 2024 bewerteten 84% der Mitarbeiter Myriad als einen großartigen Arbeitsplatz, 27 Prozentpunkte höher als das durchschnittliche US-Unternehmen. Das Unternehmen hat während des Berichtszeitraums auch 46,9 Tonnen Plastik aus seinen Laboren in Salt Lake City recycelt.
Diese Bemühungen spiegeln Myriads Mission wider, genetische Tests zugänglicher zu machen, Patienten bei der Gesundheitsverwaltung zu unterstützen und Gesundheitsdienstleistern bei der Prävention und Behandlung von Krankheiten zu helfen.
- 88% of samples processed within industry-leading turnaround times.
- Net promoter score of 72 among providers as of July 2024.
- 84% of employees rated Myriad as a great place to work, 27 percentage points higher than the typical U.S. company.
- Recycled 46.9 tons of plastic from Salt Lake City laboratories.
- None.
SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate Responsibility Report, highlighting key efforts that reflect its commitment to conduct operations as a responsible corporation in the healthcare industry.
“Quality, innovation and corporate responsibility are at the heart of what we do at Myriad Genetics,” said Paul J. Diaz, President and CEO, Myriad Genetics. “In concert with our mission to advance health and well-being for all, we continue to execute our long-term strategic growth plan, driving sustained progress and impact. This report reflects our progress on how we are making genetic testing more accessible, helping patients take more control of their health, and enabling providers to better prevent and treat disease.”
Highlights of the report, which reflect the 21-month period of Jan. 1, 2023 through Sept. 30, 2024 (the “Reporting Period”), include:
- Continued operational excellence: Through a quality management system that documents our best practices, Myriad shared success in several categories including
88% of samples being processed within what we believe are industry-leading turnaround-times. Further, the company achieved a 72 net promoter score among current providers across its testing portfolio through July 2024. - Commitment to innovation: Myriad continues to develop new technologies like molecular residual disease (MRD) assay and bring innovations to existing products. Its Labs of the Future initiative has resulted in modernized facilities that are expected to yield improved workflows, faster turnaround times and reduced operating costs.
- Being a good corporate partner: In addition to corporate governance, Myriad showcased its retention and recruitment, sustainability and community relations efforts. From a people standpoint, in 2024,
84% of employees said Myriad is a great place to work, which was 27 percentage points higher than the typical U.S. company. Further, in the Reporting Period, the company recycled 46.9 tons of plastic from its Salt Lake City laboratories.
For more information about Myriad’s quality, innovation and corporate responsibility, please read the report here.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that the company's Labs of the Future are expected to yield improved workflows, faster turnaround times and reduced operating costs. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
FAQ
What period does the Myriad Genetics Quality, Innovation, and Corporate Responsibility Report cover?
What percentage of samples did Myriad Genetics process within industry-leading turnaround times?
What net promoter score did Myriad Genetics achieve among providers?
What innovations has Myriad Genetics developed recently?
How did Myriad Genetics perform in terms of employee satisfaction in 2024?
How much plastic did Myriad Genetics recycle from its Salt Lake City laboratories?
